Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings ... All You Need to Know About Masimo Masimo Corp is a global technology company. The company's segment includes healthcare ...

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

Needham analyst Michael Matson reiterated a Buy rating on Enovis (ENOV – Research Report) today and set a price target of $65.00. Michael ...

McKesson Corporation MCK is scheduled to report second-quarter fiscal 2025 results on Nov. 6, after market close. The company ...